In addition, ADAM17 protein levels were significantly reduced in lung and breast cancer cells treated with nucleoside compounds, such as CD, TQ, and m62A. CD significantly decreased the area of fluorescence of GFP-positive syncytia compared to the control group. This evidence concerns the gene ADAM17 and breast carcinoma.